{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T03:24:01Z","timestamp":1795231441067,"version":"4.10.3"},"reference-count":65,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Card Fail Rev"],"abstract":"<jats:p>Congestion is the hallmark and the main therapeutic target in patients with decompensated heart failure (HF). Residual clinical congestion is defined as a high left ventricular diastolic pressure associated with signs and symptoms of HF, such as dyspnoea, rales and oedema, persisting despite guideline-directed medical treatment. Residual congestion in the predischarge and early post-discharge phase is the major risk factor for HF readmission and mortality. Therefore, prompt recognition of congestion and rapid optimisation of medical and device therapy are crucial to induce remission in this malignant process. In this paper we discuss the definitions, prevalence and prognosis of HF decompensation; the significance of assessing residual congestion in HF patients; the results of observational and randomised clinical trials to detect and treat residual congestion; and the current guidelines to prevent recurrent HF decompensation in the context of residual congestion. Strategies to detect and address residual congestion are crucial to stopping readmissions after an acute HF hospitalisation and improving long-term prognosis.<\/jats:p>","DOI":"10.15420\/cfr.2024.24","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T11:17:10Z","timestamp":1742815030000},"source":"Crossref","is-referenced-by-count":16,"title":["Addressing \u2018Residual Congestion\u2019 to Improve Prognosis After Acute Heart Failure Decompensation"],"prefix":"10.15420","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-7587","authenticated-orcid":false,"given":"Aleksandra","family":"G\u0105secka","sequence":"first","affiliation":[{"name":"Department of Cardiology, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-3626","authenticated-orcid":false,"given":"Aleksander","family":"Siniarski","sequence":"additional","affiliation":[{"name":"Department of Coronary Artery Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, Krak\u00f3w, Poland; St John Paul II Hospital, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342\u201356. https:\/\/doi.org\/10.1002\/ejhf.1858; PMID:\u00a032483830.","DOI":"10.1002\/ejhf.1858"},{"key":"ref1","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789\u2013858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7; PMID:\u00a030496104."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk In Communities study). Am J Cardiol 2008;101:1016\u201322. https:\/\/doi.org\/10.1016\/j.amjcard.2007.11.061; PMID:\u00a018359324.","DOI":"10.1016\/j.amjcard.2007.11.061"},{"key":"ref3","unstructured":"McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID:\u00a034447992."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:996\u20131004. https:\/\/doi.org\/10.1001\/jamainternmed.2015.0924; PMID:\u00a025895156.","DOI":"10.1001\/jamainternmed.2015.0924"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? Heart 2002;87:75\u20136. https:\/\/doi.org\/10.1136\/heart.87.1.75; PMID:\u00a011751672.","DOI":"10.1136\/heart.87.1.75"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Barasa A, Schaufelberger M, Lappas G, et al. Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. Eur Heart J 2014;35:25\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/eht278; PMID:\u00a023900697.","DOI":"10.1093\/eurheartj\/eht278"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Jhund PS, MacIntyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009;119:515\u201323. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.812172; PMID:\u00a019153268.","DOI":"10.1161\/circulationaha.108.812172"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Lawson CA, Zaccardi F, Squire I, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health 2019;4:e406\u201320. https:\/\/doi.org\/10.1016\/S2468-2667(19)30108-2; PMID:\u00a031376859.","DOI":"10.1016\/s2468-2667(19)30108-2"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Nessler J, Siniarski A, Leszek P, et al. Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. Kardiol Pol 2021;79:363\u201370. https:\/\/doi.org\/10.33963\/KP.15859; PMID:\u00a033687868.","DOI":"10.33963\/kp.15859"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Uchmanowicz I, Lisiak M, Lelonek M, et al. A curriculum for heart failure nurses: an expert opinion of the Section of Nursing and Medical Technicians and the Heart Failure Working Group of the Polish Cardiac Society. Kardiol Pol 2020;78:647\u201352. https:\/\/doi.org\/10.33963\/KP.15405; PMID:\u00a032486627.","DOI":"10.33963\/kp.15405"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137\u201346. https:\/\/doi.org\/10.1136\/hrt.2003.025270; PMID:\u00a017699180.","DOI":"10.1136\/hrt.2003.025270"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Ali MR, Lam CSP, Str\u00f6mberg A, et al. Symptoms and signs in patients with heart failure: association with 3-month hospitalisation and mortality. Heart 2024;110:578\u201385. https:\/\/doi.org\/10.1136\/heartjnl-2023-323295; PMID:\u00a038040451.","DOI":"10.1136\/heartjnl-2023-323295"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Raffaello WM, Henrina J, Huang I, et al. Clinical characteristics of de novo heart failure and acute decompensated chronic heart failure: are they distinctive phenotypes that contribute to different outcomes? Card Fail Rev 2020;7:e02. https:\/\/doi.org\/10.15420\/cfr.2020.20; PMID:\u00a033708417.","DOI":"10.15420\/cfr.2020.20"},{"key":"ref14","unstructured":"McDonagh TA, Metra M, Adamo M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368; PMID:\u00a034447992."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Mocan D, Lala RI, Puschita M, et al. The congestion \u2018pandemic\u2019 in acute heart failure patients. Biomedicines 2024;12:951. https:\/\/doi.org\/10.3390\/biomedicines12050951; PMID:\u00a038790913.","DOI":"10.3390\/biomedicines12050951"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep 2017;14:385\u201392. https:\/\/doi.org\/10.1007\/s11897-017-0351-y; PMID:\u00a028785969.","DOI":"10.1007\/s11897-017-0351-y"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Rosano GMC, Seferovic P, Savarese G, et al. Impact analysis of heart failure across European countries: an ESC-HFA position paper. ESC Heart Fail 2022;9:2767\u201378. https:\/\/doi.org\/10.1002\/ehf2.14076; PMID:\u00a035869679.","DOI":"10.1002\/ehf2.14076"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Chioncel O, Benson L, Crespo-Leiro MG, et al. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term Registry. Eur J Prev Cardiol 2023;30:1346\u201358. https:\/\/doi.org\/10.1093\/eurjpc\/zwad151; PMID:\u00a037172316.","DOI":"10.1093\/eurjpc\/zwad151"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Mir\u00f3 \u00d2, Garc\u00eda Sarasola A, Fuenzalida C, et al. Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort. Eur J Heart Fail 2019;21:1231\u201344. https:\/\/doi.org\/10.1002\/ejhf.1567; PMID:\u00a031389111.","DOI":"10.1002\/ejhf.1567"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123\u201333. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.053; PMID:\u00a024491689.","DOI":"10.1016\/j.jacc.2013.11.053"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005;96:5G\u201310G. https:\/\/doi.org\/10.1016\/j.amjcard.2005.07.015; PMID:\u00a016181818.","DOI":"10.1016\/j.amjcard.2005.07.015"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797\u2013804. https:\/\/doi.org\/10.1016\/s0735-1097(03)00309-7; PMID:\u00a012767667.","DOI":"10.1016\/s0735-1097(03)00309-7"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail 2015;8:741\u20138. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001957; PMID:\u00a026041600.","DOI":"10.1161\/circheartfailure.114.001957"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the Everest trial. Eur Heart J 2013;34:835\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehs444; PMID:\u00a023293303.","DOI":"10.1093\/eurheartj\/ehs444"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status \u2013 impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2019;21:1338\u201352. https:\/\/doi.org\/10.1002\/ejhf.1492; PMID:\u00a031127678.","DOI":"10.1002\/ejhf.1492"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Rubio-Gracia J, Demissei BG, ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol 2018;258:185\u201391. https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.067; PMID:\u00a029544928.","DOI":"10.1016\/j.ijcard.2018.01.067"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Kristj\u00e1nsd\u00f3ttir I, Thorvaldsen T, Lund LH. Congestion and diuretic resistance in acute or worsening heart failure. Card Fail Rev 2020;6:e25. https:\/\/doi.org\/10.15420\/cfr.2019.18; PMID:\u00a033042585.","DOI":"10.15420\/cfr.2019.18"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Testani JM, Brisco MA, Kociol RD, et al. Substantial discrepancy between fluid and weight loss during acute decompensated heart failure treatment. Am J Med 2015;128:776\u201383.e4. https:\/\/doi.org\/10.1016\/j.amjmed.2014.12.020; PMID:\u00a025595470.","DOI":"10.1016\/j.amjmed.2014.12.020"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137\u201355. https:\/\/doi.org\/10.1002\/ejhf.1369; PMID:\u00a030600580.","DOI":"10.1002\/ejhf.1369"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Coiro S, Rossignol P, Ambrosio G, et al. Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure. Eur J Heart Fail 2015;17:1172\u201381. https:\/\/doi.org\/10.1002\/ejhf.344; PMID:\u00a026417699.","DOI":"10.1002\/ejhf.344"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Platz E, Merz AA, Jhund PS, et al. Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. Eur J Heart Fail 2017;19:1154\u201363. https:\/\/doi.org\/10.1002\/ejhf.839; PMID:\u00a028557302.","DOI":"10.1002\/ejhf.839"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Domingo M, Lup\u00f3n J, Girerd N, et al. Lung ultrasound in outpatients with heart failure: the wet-to-dry HF study. ESC Heart Fail 2021;8:4506\u201316. https:\/\/doi.org\/10.1002\/ehf2.13660; PMID:\u00a034725962.","DOI":"10.1002\/ehf2.13660"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Cooper LB, Lippmann SJ, DiBello JR, et al. The burden of congestion in patients hospitalized with acute decompensated heart failure. Am J Cardiol 2019;124:545\u201353. https:\/\/doi.org\/10.1016\/j.amjcard.2019.05.030; PMID:\u00a031208702.","DOI":"10.1016\/j.amjcard.2019.05.030"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Aida K, Nagao K, Kato T, et al. Prognostic value of the severity of clinical congestion in patients hospitalized for decompensated heart failure: findings from the Japanese KCHF registry. J Card Fail 2023;29:1150\u201362. https:\/\/doi.org\/10.1016\/j.cardfail.2023.01.003; PMID:\u00a036690136.","DOI":"10.1016\/j.cardfail.2023.01.003"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Odajima S, Fujimoto W, Kuroda K, et al. Association of congestion with worsening renal function in acute decompensated heart failure according to age. ESC Heart Fail 2022;9:4250\u201361. https:\/\/doi.org\/10.1002\/ehf2.14157; PMID:\u00a036113882.","DOI":"10.1002\/ehf2.14157"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Ji RQ, Wang B, Zhang JG, et al. Independent prognostic value of the congestion and renal index in patients with acute heart failure. J Geriatr Cardiol 2023;20:516\u201326. https:\/\/doi.org\/10.26599\/1671-5411.2023.07.006; PMID:\u00a037576479.","DOI":"10.26599\/1671-5411.2023.07.006"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Voordes G, Davison B, Biegus J, et al. Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: data from STRONG-HF. Eur J Heart Fail 2024;26:1480\u201392. https:\/\/doi.org\/10.1002\/ejhf.3336; PMID:\u00a038874185.","DOI":"10.1002\/ejhf.3406"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Rivas-Lasarte M, \u00c1lvarez-Garc\u00eda J, Fern\u00e1ndez-Mart\u00ednez J, et al. Lung ultrasound-guided treatment in ambulatory patients with heart failure: a randomized controlled clinical trial (LUS-HF study). Eur J Heart Fail 2019;21:1605\u201313. https:\/\/doi.org\/10.1002\/ejhf.1604; PMID:\u00a031667987.","DOI":"10.1002\/ejhf.1604"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Shochat MK, Shotan A, Blondheim DS, et al. Non-invasive lung impedance-guided preemptive treatment in chronic heart failure patients: a randomized controlled trial (IMPEDANCE-HF trial). J Card Fail 2016;22:713\u201322. https:\/\/doi.org\/10.1016\/j.cardfail.2016.03.015; PMID:\u00a027058408.","DOI":"10.1016\/j.cardfail.2016.03.015"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Burgos LM, Vila RB, Goyeneche A, et al. Design and rationale of the inferior vena CAVA and Lung UltraSound-guided therapy in Acute Heart Failure (CAVAL US-AHF Study): a randomised controlled trial. Open Heart 2022;9:e002105. https:\/\/doi.org\/10.1136\/openhrt-2022-002105; PMID:\u00a036344108.","DOI":"10.1136\/openhrt-2022-002105"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Zhu Y, Li N, Wu M, et al. Impact of B-lines-guided intensive heart failure management on outcome of discharged heart failure patients with residual B-lines. ESC Heart Fail 2022;9:2713\u20138. https:\/\/doi.org\/10.1002\/ehf2.13988; PMID:\u00a035595501.","DOI":"10.1002\/ehf2.13988"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Verbrugge FH, Martens P, Ameloot K, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail 2019;21:1415\u201322. https:\/\/doi.org\/10.1002\/ejhf.1478; PMID:\u00a031074184.","DOI":"10.1002\/ejhf.1478"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022;387:1185\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2203094; PMID:\u00a036027559.","DOI":"10.1056\/NEJMoa2203094"},{"key":"ref44","unstructured":"Trull\u00e0s JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J 2023;44:411\u201321. https:\/\/doi.org\/10.1093\/eurheartj\/ehac689; PMID:\u00a036423214."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Cox ZL, Collins SP, Hernandez GA, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol 2024;83:1295\u2013306. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.009; PMID:\u00a038569758.","DOI":"10.1016\/j.jacc.2024.02.009"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 2020;22:713\u201322. https:\/\/doi.org\/10.1002\/ejhf.1713; PMID:\u00a031912605.","DOI":"10.1002\/ejhf.1713"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Schulze PC, Bogoviku J, Westphal J, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 2022;146:289\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059038; PMID:\u00a035766022.","DOI":"10.1161\/circulationaha.122.059038"},{"key":"ref48","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;2022:568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1; PMID:\u00a035228754."},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022;400:1938\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1; PMID:\u00a036356631.","DOI":"10.1016\/s0140-6736(22)02076-1"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Bilgeri V, Spitaler P, Puelacher C, et al. Decongestion in acute heart failure \u2013 time to rethink and standardize current clinical practice? J Clin Med 2024;13:311. https:\/\/doi.org\/10.3390\/jcm13020311; PMID:\u00a038256444.","DOI":"10.3390\/jcm13020311"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Cotter G, Davison BA, Lam CSP, et al. Acute heart failure is a malignant process: but we can induce remission. J Am Heart Assoc 2023;12:e031745. https:\/\/doi.org\/10.1161\/JAHA.123.031745; PMID:\u00a037889197.","DOI":"10.1161\/jaha.123.031745"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Rivas-Lasarte M, Maestro A, Fern\u00e1ndez-Mart\u00ednez J, et al. Prevalence and prognostic impact of subclinical pulmonary congestion at discharge in patients with acute heart failure. ESC Heart Fail 2020;7:2621\u20138. https:\/\/doi.org\/10.1002\/ehf2.12842; PMID:\u00a032633473.","DOI":"10.1002\/ehf2.12842"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:1482\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.696906; PMID:\u00a017724259.","DOI":"10.1161\/circulationaha.107.696906"},{"key":"ref54","unstructured":"McDonagh TA, Metra M, Adamo M, et al. Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2023;44:3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195; PMID:\u00a037622666."},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Jayaram NM, Khariton Y, Krumholz HM, et al. Impact of telemonitoring on health status. Circ Cardiovasc Qual Outcomes 2017;10:e004148. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.117.004148; PMID:\u00a029237746.","DOI":"10.1161\/circoutcomes.117.004148"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Kalter-Leibovici O, Freimark D, Freedman LS, et al. Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial. BMC Med 2017;15:90. https:\/\/doi.org\/10.1186\/s12916-017-0855-z; PMID:\u00a028457231.","DOI":"10.1186\/s12916-017-0855-z"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016;387:453\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(15)00723-0; PMID:\u00a026560249.","DOI":"10.1016\/s0140-6736(15)00723-0"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Lindenfeld JA, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021;398:991\u20131001. https:\/\/doi.org\/10.1016\/S0140-6736(21)01754-2; PMID:\u00a034461042.","DOI":"10.1016\/s0140-6736(21)01754-2"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Georges G, Fudim M, Burkhoff D, et al. Patient selection and end point definitions for decongestion studies in acute decompensated heart failure: part 1. J Soc Cardiovasc Angiogr Interv 2023;2:101060. https:\/\/doi.org\/10.1016\/j.jscai.2023.101060; PMID:\u00a039131061.","DOI":"10.1016\/j.jscai.2023.101060"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Metra M, Adamo M, Tomasoni D, et al. Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: a scientific statement by the Heart Failure Association of the ESC. Eur J Heart Fail 2023;25:1115\u201331. https:\/\/doi.org\/10.1002\/ejhf.2888; PMID:\u00a037448210.","DOI":"10.1002\/ejhf.2888"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Rosano GMC, Vitale C, Adamo M, Metra M. Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. J Cardiovasc Med (Hagerstown) 2022;23:149\u201356. https:\/\/doi.org\/10.2459\/JCM.0000000000001221; PMID:\u00a034937849.","DOI":"10.2459\/jcm.0000000000001221"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Ponikowski P, Mentz RJ, Hernandez AF, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J 2023;44:5077\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehad586; PMID:\u00a037632415.","DOI":"10.1093\/eurheartj\/ehad586"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Stevenson LW, Ross HJ, Rathman LD, Boehmer JP. Remote monitoring for heart failure management at home: JACC scientific statement. J Am Coll Cardiol 2023;81:2272\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.010; PMID:\u00a037286258.","DOI":"10.1016\/j.jacc.2023.04.010"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Burgos LM, Baro RC, Ballari FN, et al. Inferior vena CAVA and Lung UltraSound-guided therapy in Acute Heart Failure: a randomized pilot study (CAVAL US-AHF study). Am Heart J 2024;277:47\u201357. https:\/\/doi.org\/10.1016\/j.ahj.2024.07.015; PMID:\u00a039094839.","DOI":"10.1016\/j.ahj.2024.07.015"}],"container-title":["Cardiac Failure Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2024.24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T11:19:18Z","timestamp":1742815158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cfrjournal.com\/articleindex\/cfr.2024.24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":65,"URL":"https:\/\/doi.org\/10.15420\/cfr.2024.24","relation":{},"ISSN":["2057-7559","2057-7540"],"issn-type":[{"value":"2057-7559","type":"electronic"},{"value":"2057-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"article-number":"e06"}}